AI Article Synopsis
- Intranasal esketamine is the only form of ketamine approved for treatment of resistant depression, costing around $600 per dose compared to less than $20 for injected ketamine.
- Research indicates that intranasal esketamine is less effective and has more side effects than the traditional injected version.
- The recent approval raises concerns about adopting a less effective treatment, even if it's part of the regulatory process for medicine approval.
Article Abstract
Background: Intranasal esketamine has been recently approved for the treatment of resistant depression. It is the only form of ketamine approved. The formulation costs around $600 per dose while plain injected ketamine, on which most research has been done, costs less than $20 per dose. Research shows that intranasal esketamine is less effective and has more unwanted effects than injected ketamine, yet the approval means that this intranasal formulation will now be the form used and researched.
Conclusion: While the approval of an inferior treatment mode is understandable from the processes by which medicines are approved, we should think carefully about embracing this particular form of a promising treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/10398562221093870 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Optimal doses of intranasal esketamine plus dexmedetomidine for sedating toddlers during transthoracic echocardiography: a prospective, double-blind, randomized trial.
Ann Med
December 2025
Department of Anesthesiology, Hunan Children's Hospital, Changsha, Hunan, China.
Introduction: Esketamine has unique advantages in combination with dexmedetomidine for sedation in young children, owing to its sympathetic activity and mild respiratory depression. However, the optimal dose is yet to be determined. In this study, we compared the different doses of intranasal esketamine combined with dexmedetomidine for sedation during transthoracic echocardiography in toddlers.
View Article and Find Full Text PDFEsketamine Treatment Trajectory of Patients with Treatment-Resistant Depression in the Mid and Long-Term Run: Data from REAL-ESK Study Group.
Curr Neuropharmacol
January 2025
Department of Neurosciences 'Rita Levi Montalcini', University of Torino, Turin, Italy.
Introduction/objective: Data on long-term treatment with Esketamine Nasal Spray (ESKNS) in real-world patients with treatment resistant depression (TRD) is scarce. The primary aim of the study is to evaluate the effectiveness and tolerability of ESK-NS treatment at 6 and 12-month follow-ups.
Methods: This is part of an observational, retrospective, multicentric Italian study (REAL-ESK study).
Safety outcomes of ketamine for treatment-resistant depression in clinical settings and development of the ketamine side effect tool-revised (KSET-R).
Psychiatry Res
February 2025
Black Dog Institute, Sydney, Australia; Discipline of Psychiatry and Mental Health, School of Clinical Medicine, University of New South Wales, Australia; The George Institute for Global Health, Sydney, Australia.
Background: Ketamine and its derivates (e.g. esketamine) are increasingly used in clinical settings for treatment-resistant depression (TRD).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!